Zobrazeno 1 - 10
of 615
pro vyhledávání: ''
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Alvin M. Matsumoto, Nima Sharifi, Michael T. Schweizer, Heather H. Cheng, R. Bruce Montgomery, Mary-Ellen Taplin, P.W. Kantoff, Felix S. Chew, Evan Y. Yu, Orpheus Kolokythas, Steven P. Balk, Peter S. Nelson, Brett T. Marck, Elahe A. Mostaghel
Publikováno v:
Clin Cancer Res
Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in castration-resistant prostate
Autor:
David Marin, Elias Jabbour, Denái R. Milton, Amanda Olson, Gabriela Rondon, Jin S. Im, Rohtesh S. Mehta, Uday R. Popat, May Daher, Felipe Samaniego, Loretta J. Nastoupil, Neeraj Saini, Celina Ledesma, Paolo Anderlini, Muzaffar H. Qazilbash, Qaiser Bashir, Issa F. Khouri, Alison M. Gulbis, Richard E. Champlin, L. Jeffrey Medeiros, Swaminathan P. Iyer
Publikováno v:
Clinical Cancer Research. 27:5847-5856
Purpose: To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). Patients and Methods: We evaluated 19
Autor:
Amy E. DeZern, Alan F. List, Jeffrey E. Lancet, Hannah Newman, Eric Padron, Maria E. Balasis, Mikkael A. Sekeres, Rami S. Komrokji, Anthony M. Hunter, Qianxing Mo, Traci Kruer, Sandrine Niyongere, Markus Ball, Christopher Letson, Aaron T. Gerds, Gail J. Roboz, David A. Sallman, Hailing Zhang, Onyee Chan, David P. Steensma, William Dominguez-Viqueira
Publikováno v:
Clinical Cancer Research. 27:6095-6105
Purpose: Chronic myelomonocytic leukemia (CMML) is a rare leukemia characterized by peripheral monocytosis with no disease-modifying therapies. CMML cells are uniquely hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and ro
Autor:
Manish R. Patel, Peng He, Antoinette R. Tan, Anita Scheuber, Shannon Marshall, Anton I. Rosenbaum, Kemal Balic, Erika Hamilton, Mark D. Pegram, Mayukh Das, Meina Liang, Anna Maria Storniolo
Publikováno v:
Molecular Cancer Therapeutics. 20:1442-1453
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-based microtubule inhibitor payload. MEDI4276 demonstrates enhanced cell
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Autor:
Rachel E. Sanborn, John E. Leonard, Crystal Mallow, Megan Ann Baumgart, Andreas Schröder, Nashat Y. Gabrail, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer, Nagashree Seetharamu, JT Beck, Michael Shafique, Elizabeth E. Evans, Desa Rae Pastore, Ramaswamy Govindan, Ernest S. Smith, Kevin M. Chin, Yanyan Lou, Terrence L. Fisher, Vikas Mishra, Alexander I. Spira
Publikováno v:
Clinical Cancer Research. 27:3630-3640
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune su
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
David M. Hyman, Lynette M. Sholl, Katherine Kargus, Hebert Alberto Vargas, Ann E. Sisk, Elio Adib, James J. Harding, Solida Pruitt-Thompson, Krinio Giannikou, Jennifer Hedglin, Martin H. Voss, Khanh T. Do, Ketki Bhushan, Matthew I. Milstein, David J. Kwiatkowski, Gopa Iyer, Geoffrey I. Shapiro, Junko Tsuji, Katarzyna Klonowska
Publikováno v:
Clinical Cancer Research. 27:3845-3853
Purpose:This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations.Patients and M
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma